Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Centessa Pharmaceuticals plc

Get SEC filing alerts via email and in your feed for Centessa Pharmaceuticals plc

CNTA

Centessa Pharmaceuticals plc

About Centessa Pharmaceuticals plc

Centessa Pharmaceuticals is a clinical-stage biotech focused on discovering and developing transformative medicines, including orexin receptor 2 (OX2R) agonists for sleep and neurodegenerative disorders, and innovative immuno-oncology therapies using its LockBody platform. It targets neurological, neuropsychiatric, and cancer indications, leveraging proprietary technology and strategic licensing. The company relies on third-party manufacturing, collaborates with partners, and navigates complex regulatory pathways to bring novel treatments to market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Centessa Pharmaceuticals plc

1
1
Centessa Pharmaceuticals plc Centessa Pharmaceuticals Reports $79.2 Million Net Loss and $0 Revenue for Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Centessa Pharmaceuticals plc Centessa Pharmaceuticals Reports $197.5M Net Loss for 2025, Announces Acquisition by Eli Lilly

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Centessa Pharmaceuticals plc Centessa Pharmaceuticals Reports $54.9 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Centessa Pharmaceuticals plc Centessa Pharmaceuticals Reports Q2 2025 Financial Results with Increased Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Centessa Pharmaceuticals plc Centessa Pharmaceuticals Reports $15M Revenue and $26.1M Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Centessa Pharmaceuticals plc Centessa Pharmaceuticals Reports $235.7 Million Net Loss for 2024, Discontinues Key Programs

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Centessa Pharmaceuticals plc Centessa Pharmaceuticals Reports Q3 2024 Financial Results, Net Losses, and Strategic Developments

Via official filing (AI summary) | over 1 year ago | 0 comments